Entity

Time filter

Source Type


Amengual J.L.,Cognition and Brain Plasticity Group Bellvitge Biomedical Research Institute | Amengual J.L.,University of Barcelona | Rojo N.,Cognition and Brain Plasticity Group Bellvitge Biomedical Research Institute | Rojo N.,University of Barcelona | And 20 more authors.
PLoS ONE | Year: 2013

Background:Several recently developed therapies targeting motor disabilities in stroke sufferers have shown to be more effective than standard neurorehabilitation approaches. In this context, several basic studies demonstrated that music training produces rapid neuroplastic changes in motor-related brain areas. Music-supported therapy has been recently developed as a new motor rehabilitation intervention.Methods and Results:In order to explore the plasticity effects of music-supported therapy, this therapeutic intervention was applied to twenty chronic stroke patients. Before and after the music-supported therapy, transcranial magnetic stimulation was applied for the assessment of excitability changes in the motor cortex and a 3D movement analyzer was used for the assessment of motor performance parameters such as velocity, acceleration and smoothness in a set of diadochokinetic movement tasks. Our results suggest that the music-supported therapy produces changes in cortical plasticity leading the improvement of the subjects' motor performance.Conclusion:Our findings represent the first evidence of the neurophysiological changes induced by this therapy in chronic stroke patients, and their link with the amelioration of motor performance. Further studies are needed to confirm our observations. © 2013 Amengual et al. Source


Miro J.,Epilepsy Unit | Miro J.,Cognition and Brain Plasticity Group Bellvitge Biomedical Research Institute | Toledo M.,Hospital Universitari Of La Vall Dhebron | Santamarina E.,Hospital Universitari Of La Vall Dhebron | And 7 more authors.
Seizure | Year: 2013

Objective: Treatment of status epilepticus (SE) has not changed in the last few decades, benzodiazepines plus phenytoin or valproate being the most common treatment. Once this first and second line treatment has failed SE is considered refractory (RSE). This study aimed to assess the efficacy and tolerability of intravenous (iv) lacosamide (LCM) in RSE. Method: Patients with RSE who were treated with ivLCM in six Spanish centers were prospectively included. Efficacy was defined as cessation of seizures after starting ivLCM, with no need for any further antiepileptic drug. All patients had been unsuccessfully treated following the standard protocol (benzodiazepines plus phenytoin or valproate) before ivLCM was added. Results: Thirty-four patients were included, 52.9% men, with mean age of 60.15 years. In 58.9% of patients the etiology was symptomatic, and the most common type of SE was focal convulsive (82.4%). Mean initial bolus dose of LCM was 323.53 mg. ivLCM was effective in more than half of patients (64.7%), with termination of SE before 12 h in 50% of them. ivLCM was used as a fourth or later option in 76.5% of patients. No serious adverse events attributable to LCM were reported. Conclusions: LCM might be a fast, effective and safe add-on treatment in RSE. © 2012 British Epilepsy Association. Source


Miro J.,Hospital Universitari Of Bellvitge | Miro J.,Cognition and Brain Plasticity Group Bellvitge Biomedical Research Institute | Fortuny R.,Hospital Universitari Of Bellvitge | Juncadella M.,Hospital Universitari Of Bellvitge | And 7 more authors.
Clinical Neurology and Neurosurgery | Year: 2014

In one third of patients with epilepsy starting in adulthood the aetiology remains undetermined. Some patients with late onset temporal lobe epilepsy (TLE) together with memory decline have elevated antithyroid antibodies. Purpose To compare the prevalence of antithyroid antibodies (aTR-ab) in adult onset temporal lobe epilepsy (TLE) patients with known and unknown TLE aetiology (N = 42). Moreover, the sera of these patients was also assayed for antinuclear antibodies (ANA), anticardiolipin antibodies (ACL), anti glutamic acid decarboxylase antibodies (GAD) and antiglidadin antibodies. Results Positive aTR-ab in the sera of patients with unknown aetiology was 11/23 (47.8%) vs. 1/19 (4.3%) in the group with known aetiology (p = 0.005). In 9/11 (81%) a pre-existing autoimmune disease was confirmed. Nine (81%) were women and five (45%) had memory impairment. There were 5/11 (45%) pharmacoresistant patients, and corticosteroid treatment was initiated in 3/5 with cognitive and seizure improvement. The results of other immunological tests were only remarkable for antiGAD antibodies with 3/11 (27%) positive patients, but this subgroup does not have any significant clinical differential feature. Conclusions Late-onset TLE with positive aTR-ab tends to be middle-aged women with nonpharmacoresistant cryptogenic epilepsy plus cognitive decline and other associated autoimmune diseases. It could be advisable to test aTR-ab in TLE patients with an unknown aetiology, in order to improve diagnosis and resulting treatment. © 2014 Elsevier B.V. Source

Discover hidden collaborations